Novartis
NEWS
The two generic drugmakers, along with many others, have been accused of conspiring to inflate the price of more than 100 generic drugs.
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
Today has been marked by a wide range of life science and biopharma stories. Here’s a broader look at some of the top stories.
The sale of Xiidra to Novartis and TachoSil to Ethicon is part of Takeda’s strategy to pare down debt from its $62 billion acquisition of Shire.
On March 27, the U.S. Food and Drug Administration (FDA) approved Novartis’ Mayzent (isiponimod) for adults with relapsing types of multiple sclerosis.
Quite a few companies recently released results from late-stage clinical trials. Here’s a look at some of the top stories, from AveXis, Urovant, Lilly, and more.
SMA is a severe neuromuscular disease caused by a mutation in the SMN1 gene, which codes for SMN, a protein necessary for motor neuron function.
There has been a string of news stories about how big pharma is teaming up with various artificial intelligence (AI) companies to leverage real-world data and speed drug development.
Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors
JOBS
IN THE PRESS